Citron Research

Nio Inc's (NYSE: NIO) scintillating rally came to a screeching halt Friday after short seller Citron Research spoiled the party by suggesting the EV maker's astronomical valuation becomes unjustifiable. Nio's Rally and The Hard Fall: Nio's stock, which ended 2019 at $4.02, began to...

Two years after Citron Research editor and notorious short seller Andrew Left made a bold bullish call on Nio Inc - ADR (NYSE: NIO), Left said Friday it’s finally time for investors to cash out of the red-hot EV stock. Back in November 2018, Left compared Nio to Tesla Inc (NASDAQ: TSLA)...

Leading African e-commerce company Jumia Technologies (NYSE: JMIA) reported third-quarter earnings Tuesday morning. Shares fell on a decline in revenue, but the move could be overdone as the company shifts its business to improve profitability. Earnings: The gross merchandise value fell 28% year-...

Citron Research has gone from bearish to bullish on Jumia Technologies, a Berlin-based e-commerce company operating in Africa.  The Citron Bullish Case: Citron Research flagged problems at Jumia Technologies (NYSE: JMIA) in May 2019 that it said included financial discrepancies,...

Shares of Fluidigm Corporation (NASDAQ: FLDM) were surging Monday following a decision by the Trump administration to use the company's saliva test for SARS-CoV-2, the virus that causes COVID-19. What Happened: As part of a federal surge testing effort for COVID-19, the saliva test made by...

Shares of the African e-commerce company are up sharply Friday. About Jumia: Jumia Technologies (NYSE: JMIA) is an e-commerce company in Africa with operations in 11 countries in the continent. The company operates its Jumia Logistics and Jumia Pay businesses and also recently launched gaming...

BofA Securities recently hosted its fifth annual Future Car Conference. This year’s event featured 11 auto industry expert speakers discussing the leading trends in the future of the global auto industry like electrification, software, autonomy, hydrogen fuel cells, ride-hailing and the...

Auto technology stocks certainly have Wall Street’s attention this year. Young investors appear to see next-generation auto technology as a major long-term investment opportunity. Autonomous vehicle technology is one of the biggest investment themes in the auto market these days, and Mizuho...

Citron Research editor and notorious short seller Andrew Left discussed one of his latest stock ideas during an appearance on Benzinga’s PreMarket Prep show this week. COMPASS Pathways PLC (NASDAQ: CMPS) shares may have ended Tuesday's session down 3.76%, but Left has a bullish thesis for...

Citron Research founder and activist short seller Andrew Left discussed his latest ideas during an appearance on Benzinga’s PreMarket Prep show Tuesday morning. Left has gained notoriety over the years for successfully betting against Bausch Health Companies Inc (NYSE: BHC) (formerly Valeant...

Citron Research founder and notorious short-seller Andrew Left weighed in on the special acquisition company (SPAC) trend on Wall Street during an appearance on Benzinga’s PreMarket Prep show Tuesday morning. Many companies have been choosing to go public via a SPAC merger rather than the...

Inovio Pharmaceuticals Inc (NASDAQ: INO) shares were volatile Wednesday amid external developments and a presentation by CEO Joseph Kim at a health care conference. Inovio's Sympathy Move: Inovio shares, which shed about 4% Tuesday before settling at $16.98, gap-opened Wednesday down at $16.21...

Luckin Coffee Inc (OTC: LKNCY) is among a group of 45 companies fined $8.98 million for falsification of financial records and misleading the public by China’s market regulator, Reuters reported Monday. What Happened: The market regulator said its investigations established that the coffee...

Gainers Novus Therapeutics, Inc. (NASDAQ: NVUS) shares climbed 192.9% to close at $1.11 on Tuesday after the company reported the acquisition of Anelixis Therapeutics, Inc., a privately held clinical-stage biotechnology company developing a next generation anti-CD40 Ligand antibody as a potential...